1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Immune Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Immune Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Immune Drugs by Country/Region, 2018, 2022 & 2029
2.2 Immune Drugs Segment by Type
2.2.1 Immune Boosting Drugs
2.2.2 Immunosuppressant Drugs
2.3 Immune Drugs Sales by Type
2.3.1 Global Immune Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Immune Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Immune Drugs Sale Price by Type (2018-2023)
2.4 Immune Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Surgery Center
2.4.4 Others
2.5 Immune Drugs Sales by Application
2.5.1 Global Immune Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Immune Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Immune Drugs Sale Price by Application (2018-2023)
3 Global Immune Drugs by Company
3.1 Global Immune Drugs Breakdown Data by Company
3.1.1 Global Immune Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Immune Drugs Sales Market Share by Company (2018-2023)
3.2 Global Immune Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Immune Drugs Revenue by Company (2018-2023)
3.2.2 Global Immune Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Immune Drugs Sale Price by Company
3.4 Key Manufacturers Immune Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Immune Drugs Product Location Distribution
3.4.2 Players Immune Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Immune Drugs by Geographic Region
4.1 World Historic Immune Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Immune Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Immune Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Immune Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Immune Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Immune Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Immune Drugs Sales Growth
4.4 APAC Immune Drugs Sales Growth
4.5 Europe Immune Drugs Sales Growth
4.6 Middle East & Africa Immune Drugs Sales Growth
5 Americas
5.1 Americas Immune Drugs Sales by Country
5.1.1 Americas Immune Drugs Sales by Country (2018-2023)
5.1.2 Americas Immune Drugs Revenue by Country (2018-2023)
5.2 Americas Immune Drugs Sales by Type
5.3 Americas Immune Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immune Drugs Sales by Region
6.1.1 APAC Immune Drugs Sales by Region (2018-2023)
6.1.2 APAC Immune Drugs Revenue by Region (2018-2023)
6.2 APAC Immune Drugs Sales by Type
6.3 APAC Immune Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Immune Drugs by Country
7.1.1 Europe Immune Drugs Sales by Country (2018-2023)
7.1.2 Europe Immune Drugs Revenue by Country (2018-2023)
7.2 Europe Immune Drugs Sales by Type
7.3 Europe Immune Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Immune Drugs by Country
8.1.1 Middle East & Africa Immune Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Immune Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Immune Drugs Sales by Type
8.3 Middle East & Africa Immune Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Immune Drugs
10.3 Manufacturing Process Analysis of Immune Drugs
10.4 Industry Chain Structure of Immune Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Immune Drugs Distributors
11.3 Immune Drugs Customer
12 World Forecast Review for Immune Drugs by Geographic Region
12.1 Global Immune Drugs Market Size Forecast by Region
12.1.1 Global Immune Drugs Forecast by Region (2024-2029)
12.1.2 Global Immune Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Immune Drugs Forecast by Type
12.7 Global Immune Drugs Forecast by Application
13 Key Players Analysis
13.1 Antares Pharma, Inc.
13.1.1 Antares Pharma, Inc. Company Information
13.1.2 Antares Pharma, Inc. Immune Drugs Product Portfolios and Specifications
13.1.3 Antares Pharma, Inc. Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Antares Pharma, Inc. Main Business Overview
13.1.5 Antares Pharma, Inc. Latest Developments
13.2 UCB
13.2.1 UCB Company Information
13.2.2 UCB Immune Drugs Product Portfolios and Specifications
13.2.3 UCB Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 UCB Main Business Overview
13.2.5 UCB Latest Developments
13.3 Incyte
13.3.1 Incyte Company Information
13.3.2 Incyte Immune Drugs Product Portfolios and Specifications
13.3.3 Incyte Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Incyte Main Business Overview
13.3.5 Incyte Latest Developments
13.4 GSK
13.4.1 GSK Company Information
13.4.2 GSK Immune Drugs Product Portfolios and Specifications
13.4.3 GSK Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 GSK Main Business Overview
13.4.5 GSK Latest Developments
13.5 Takeda
13.5.1 Takeda Company Information
13.5.2 Takeda Immune Drugs Product Portfolios and Specifications
13.5.3 Takeda Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Takeda Main Business Overview
13.5.5 Takeda Latest Developments
13.6 3S Bio
13.6.1 3S Bio Company Information
13.6.2 3S Bio Immune Drugs Product Portfolios and Specifications
13.6.3 3S Bio Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 3S Bio Main Business Overview
13.6.5 3S Bio Latest Developments
13.7 Horizo​​n Therapeutics
13.7.1 Horizo​​n Therapeutics Company Information
13.7.2 Horizo​​n Therapeutics Immune Drugs Product Portfolios and Specifications
13.7.3 Horizo​​n Therapeutics Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Horizo​​n Therapeutics Main Business Overview
13.7.5 Horizo​​n Therapeutics Latest Developments
13.8 Bristol-Myers Squibb (BMS
13.8.1 Bristol-Myers Squibb (BMS Company Information
13.8.2 Bristol-Myers Squibb (BMS Immune Drugs Product Portfolios and Specifications
13.8.3 Bristol-Myers Squibb (BMS Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Bristol-Myers Squibb (BMS Main Business Overview
13.8.5 Bristol-Myers Squibb (BMS Latest Developments
13.9 Astellas
13.9.1 Astellas Company Information
13.9.2 Astellas Immune Drugs Product Portfolios and Specifications
13.9.3 Astellas Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Astellas Main Business Overview
13.9.5 Astellas Latest Developments
13.10 Eli Lilly
13.10.1 Eli Lilly Company Information
13.10.2 Eli Lilly Immune Drugs Product Portfolios and Specifications
13.10.3 Eli Lilly Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Eli Lilly Main Business Overview
13.10.5 Eli Lilly Latest Developments
13.11 Mitsubishi Tanabe Pharma
13.11.1 Mitsubishi Tanabe Pharma Company Information
13.11.2 Mitsubishi Tanabe Pharma Immune Drugs Product Portfolios and Specifications
13.11.3 Mitsubishi Tanabe Pharma Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Mitsubishi Tanabe Pharma Main Business Overview
13.11.5 Mitsubishi Tanabe Pharma Latest Developments
13.12 Biogen
13.12.1 Biogen Company Information
13.12.2 Biogen Immune Drugs Product Portfolios and Specifications
13.12.3 Biogen Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Biogen Main Business Overview
13.12.5 Biogen Latest Developments
13.13 Pfizer
13.13.1 Pfizer Company Information
13.13.2 Pfizer Immune Drugs Product Portfolios and Specifications
13.13.3 Pfizer Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Pfizer Main Business Overview
13.13.5 Pfizer Latest Developments
13.14 Sanofi
13.14.1 Sanofi Company Information
13.14.2 Sanofi Immune Drugs Product Portfolios and Specifications
13.14.3 Sanofi Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Sanofi Main Business Overview
13.14.5 Sanofi Latest Developments
13.15 Roche
13.15.1 Roche Company Information
13.15.2 Roche Immune Drugs Product Portfolios and Specifications
13.15.3 Roche Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Roche Main Business Overview
13.15.5 Roche Latest Developments
13.16 Novartis
13.16.1 Novartis Company Information
13.16.2 Novartis Immune Drugs Product Portfolios and Specifications
13.16.3 Novartis Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Novartis Main Business Overview
13.16.5 Novartis Latest Developments
13.17 Johnson & Johnson (J&J)
13.17.1 Johnson & Johnson (J&J) Company Information
13.17.2 Johnson & Johnson (J&J) Immune Drugs Product Portfolios and Specifications
13.17.3 Johnson & Johnson (J&J) Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Johnson & Johnson (J&J) Main Business Overview
13.17.5 Johnson & Johnson (J&J) Latest Developments
13.18 Amgen
13.18.1 Amgen Company Information
13.18.2 Amgen Immune Drugs Product Portfolios and Specifications
13.18.3 Amgen Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 Amgen Main Business Overview
13.18.5 Amgen Latest Developments
13.19 Abbvi
13.19.1 Abbvi Company Information
13.19.2 Abbvi Immune Drugs Product Portfolios and Specifications
13.19.3 Abbvi Immune Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Abbvi Main Business Overview
13.19.5 Abbvi Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Immune Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Immune Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Immune Boosting Drugs
Table 4. Major Players of Immunosuppressant Drugs
Table 5. Global Immune Drugs Sales by Type (2018-2023) & (K Units)
Table 6. Global Immune Drugs Sales Market Share by Type (2018-2023)
Table 7. Global Immune Drugs Revenue by Type (2018-2023) & ($ million)
Table 8. Global Immune Drugs Revenue Market Share by Type (2018-2023)
Table 9. Global Immune Drugs Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global Immune Drugs Sales by Application (2018-2023) & (K Units)
Table 11. Global Immune Drugs Sales Market Share by Application (2018-2023)
Table 12. Global Immune Drugs Revenue by Application (2018-2023)
Table 13. Global Immune Drugs Revenue Market Share by Application (2018-2023)
Table 14. Global Immune Drugs Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Immune Drugs Sales by Company (2018-2023) & (K Units)
Table 16. Global Immune Drugs Sales Market Share by Company (2018-2023)
Table 17. Global Immune Drugs Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Immune Drugs Revenue Market Share by Company (2018-2023)
Table 19. Global Immune Drugs Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Immune Drugs Producing Area Distribution and Sales Area
Table 21. Players Immune Drugs Products Offered
Table 22. Immune Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Immune Drugs Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Immune Drugs Sales Market Share Geographic Region (2018-2023)
Table 27. Global Immune Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Immune Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Immune Drugs Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Immune Drugs Sales Market Share by Country/Region (2018-2023)
Table 31. Global Immune Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Immune Drugs Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Immune Drugs Sales by Country (2018-2023) & (K Units)
Table 34. Americas Immune Drugs Sales Market Share by Country (2018-2023)
Table 35. Americas Immune Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Immune Drugs Revenue Market Share by Country (2018-2023)
Table 37. Americas Immune Drugs Sales by Type (2018-2023) & (K Units)
Table 38. Americas Immune Drugs Sales by Application (2018-2023) & (K Units)
Table 39. APAC Immune Drugs Sales by Region (2018-2023) & (K Units)
Table 40. APAC Immune Drugs Sales Market Share by Region (2018-2023)
Table 41. APAC Immune Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Immune Drugs Revenue Market Share by Region (2018-2023)
Table 43. APAC Immune Drugs Sales by Type (2018-2023) & (K Units)
Table 44. APAC Immune Drugs Sales by Application (2018-2023) & (K Units)
Table 45. Europe Immune Drugs Sales by Country (2018-2023) & (K Units)
Table 46. Europe Immune Drugs Sales Market Share by Country (2018-2023)
Table 47. Europe Immune Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Immune Drugs Revenue Market Share by Country (2018-2023)
Table 49. Europe Immune Drugs Sales by Type (2018-2023) & (K Units)
Table 50. Europe Immune Drugs Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Immune Drugs Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Immune Drugs Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Immune Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Immune Drugs Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Immune Drugs Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Immune Drugs Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Immune Drugs
Table 58. Key Market Challenges & Risks of Immune Drugs
Table 59. Key Industry Trends of Immune Drugs
Table 60. Immune Drugs Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Immune Drugs Distributors List
Table 63. Immune Drugs Customer List
Table 64. Global Immune Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Immune Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Immune Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Immune Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Immune Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Immune Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Immune Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Immune Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Immune Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Immune Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Immune Drugs Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Immune Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Immune Drugs Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Immune Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Antares Pharma, Inc. Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. Antares Pharma, Inc. Immune Drugs Product Portfolios and Specifications
Table 80. Antares Pharma, Inc. Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. Antares Pharma, Inc. Main Business
Table 82. Antares Pharma, Inc. Latest Developments
Table 83. UCB Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. UCB Immune Drugs Product Portfolios and Specifications
Table 85. UCB Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. UCB Main Business
Table 87. UCB Latest Developments
Table 88. Incyte Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. Incyte Immune Drugs Product Portfolios and Specifications
Table 90. Incyte Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Incyte Main Business
Table 92. Incyte Latest Developments
Table 93. GSK Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. GSK Immune Drugs Product Portfolios and Specifications
Table 95. GSK Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. GSK Main Business
Table 97. GSK Latest Developments
Table 98. Takeda Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Takeda Immune Drugs Product Portfolios and Specifications
Table 100. Takeda Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Takeda Main Business
Table 102. Takeda Latest Developments
Table 103. 3S Bio Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. 3S Bio Immune Drugs Product Portfolios and Specifications
Table 105. 3S Bio Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. 3S Bio Main Business
Table 107. 3S Bio Latest Developments
Table 108. Horizo​​n Therapeutics Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. Horizo​​n Therapeutics Immune Drugs Product Portfolios and Specifications
Table 110. Horizo​​n Therapeutics Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Horizo​​n Therapeutics Main Business
Table 112. Horizo​​n Therapeutics Latest Developments
Table 113. Bristol-Myers Squibb (BMS Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. Bristol-Myers Squibb (BMS Immune Drugs Product Portfolios and Specifications
Table 115. Bristol-Myers Squibb (BMS Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Bristol-Myers Squibb (BMS Main Business
Table 117. Bristol-Myers Squibb (BMS Latest Developments
Table 118. Astellas Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. Astellas Immune Drugs Product Portfolios and Specifications
Table 120. Astellas Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. Astellas Main Business
Table 122. Astellas Latest Developments
Table 123. Eli Lilly Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124. Eli Lilly Immune Drugs Product Portfolios and Specifications
Table 125. Eli Lilly Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 126. Eli Lilly Main Business
Table 127. Eli Lilly Latest Developments
Table 128. Mitsubishi Tanabe Pharma Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 129. Mitsubishi Tanabe Pharma Immune Drugs Product Portfolios and Specifications
Table 130. Mitsubishi Tanabe Pharma Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 131. Mitsubishi Tanabe Pharma Main Business
Table 132. Mitsubishi Tanabe Pharma Latest Developments
Table 133. Biogen Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 134. Biogen Immune Drugs Product Portfolios and Specifications
Table 135. Biogen Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 136. Biogen Main Business
Table 137. Biogen Latest Developments
Table 138. Pfizer Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 139. Pfizer Immune Drugs Product Portfolios and Specifications
Table 140. Pfizer Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 141. Pfizer Main Business
Table 142. Pfizer Latest Developments
Table 143. Sanofi Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 144. Sanofi Immune Drugs Product Portfolios and Specifications
Table 145. Sanofi Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 146. Sanofi Main Business
Table 147. Sanofi Latest Developments
Table 148. Roche Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 149. Roche Immune Drugs Product Portfolios and Specifications
Table 150. Roche Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 151. Roche Main Business
Table 152. Roche Latest Developments
Table 153. Novartis Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 154. Novartis Immune Drugs Product Portfolios and Specifications
Table 155. Novartis Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 156. Novartis Main Business
Table 157. Novartis Latest Developments
Table 158. Johnson & Johnson (J&J) Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 159. Johnson & Johnson (J&J) Immune Drugs Product Portfolios and Specifications
Table 160. Johnson & Johnson (J&J) Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 161. Johnson & Johnson (J&J) Main Business
Table 162. Johnson & Johnson (J&J) Latest Developments
Table 163. Amgen Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 164. Amgen Immune Drugs Product Portfolios and Specifications
Table 165. Amgen Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 166. Amgen Main Business
Table 167. Amgen Latest Developments
Table 168. Abbvi Basic Information, Immune Drugs Manufacturing Base, Sales Area and Its Competitors
Table 169. Abbvi Immune Drugs Product Portfolios and Specifications
Table 170. Abbvi Immune Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 171. Abbvi Main Business
Table 172. Abbvi Latest Developments
List of Figures
Figure 1. Picture of Immune Drugs
Figure 2. Immune Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Immune Drugs Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Immune Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Immune Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Immune Boosting Drugs
Figure 10. Product Picture of Immunosuppressant Drugs
Figure 11. Global Immune Drugs Sales Market Share by Type in 2022
Figure 12. Global Immune Drugs Revenue Market Share by Type (2018-2023)
Figure 13. Immune Drugs Consumed in Hospital
Figure 14. Global Immune Drugs Market: Hospital (2018-2023) & (K Units)
Figure 15. Immune Drugs Consumed in Clinic
Figure 16. Global Immune Drugs Market: Clinic (2018-2023) & (K Units)
Figure 17. Immune Drugs Consumed in Surgery Center
Figure 18. Global Immune Drugs Market: Surgery Center (2018-2023) & (K Units)
Figure 19. Immune Drugs Consumed in Others
Figure 20. Global Immune Drugs Market: Others (2018-2023) & (K Units)
Figure 21. Global Immune Drugs Sales Market Share by Application (2022)
Figure 22. Global Immune Drugs Revenue Market Share by Application in 2022
Figure 23. Immune Drugs Sales Market by Company in 2022 (K Units)
Figure 24. Global Immune Drugs Sales Market Share by Company in 2022
Figure 25. Immune Drugs Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Immune Drugs Revenue Market Share by Company in 2022
Figure 27. Global Immune Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Immune Drugs Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Immune Drugs Sales 2018-2023 (K Units)
Figure 30. Americas Immune Drugs Revenue 2018-2023 ($ Millions)
Figure 31. APAC Immune Drugs Sales 2018-2023 (K Units)
Figure 32. APAC Immune Drugs Revenue 2018-2023 ($ Millions)
Figure 33. Europe Immune Drugs Sales 2018-2023 (K Units)
Figure 34. Europe Immune Drugs Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Immune Drugs Sales 2018-2023 (K Units)
Figure 36. Middle East & Africa Immune Drugs Revenue 2018-2023 ($ Millions)
Figure 37. Americas Immune Drugs Sales Market Share by Country in 2022
Figure 38. Americas Immune Drugs Revenue Market Share by Country in 2022
Figure 39. Americas Immune Drugs Sales Market Share by Type (2018-2023)
Figure 40. Americas Immune Drugs Sales Market Share by Application (2018-2023)
Figure 41. United States Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Immune Drugs Sales Market Share by Region in 2022
Figure 46. APAC Immune Drugs Revenue Market Share by Regions in 2022
Figure 47. APAC Immune Drugs Sales Market Share by Type (2018-2023)
Figure 48. APAC Immune Drugs Sales Market Share by Application (2018-2023)
Figure 49. China Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Immune Drugs Sales Market Share by Country in 2022
Figure 57. Europe Immune Drugs Revenue Market Share by Country in 2022
Figure 58. Europe Immune Drugs Sales Market Share by Type (2018-2023)
Figure 59. Europe Immune Drugs Sales Market Share by Application (2018-2023)
Figure 60. Germany Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Immune Drugs Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Immune Drugs Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Immune Drugs Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Immune Drugs Sales Market Share by Application (2018-2023)
Figure 69. Egypt Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Immune Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Immune Drugs in 2022
Figure 75. Manufacturing Process Analysis of Immune Drugs
Figure 76. Industry Chain Structure of Immune Drugs
Figure 77. Channels of Distribution
Figure 78. Global Immune Drugs Sales Market Forecast by Region (2024-2029)
Figure 79. Global Immune Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Immune Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Immune Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Immune Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Immune Drugs Revenue Market Share Forecast by Application (2024-2029)

※参考情報 免疫薬は、免疫系に働きかける、または免疫系を利用して病気の治療を目的とする医薬品です。近年、がん治療や自己免疫疾患の治療においてますます注目を集めており、多様な種類と用途が存在します。以下では、免疫薬の概念について詳しく述べます。 免疫薬の定義としては、免疫系の機能を強化、修正、または再調整するために用いられる薬剤全般を指します。これには、がん細胞に対する免疫反応を促進するものや、過剰な免疫反応を抑制するもの、自身の免疫系を学習させ、特定の病原体や異常細胞を攻撃するようにするものなどが含まれます。免疫薬は、もともと自然に存在する免疫成分を模倣したり、補ったりすることから始まり、現在では高度な技術を用いて設計されたものも多数存在します。 免疫薬の特徴として、一つに高い特異性が挙げられます。免疫系は身体を外部の脅威から守るために進化しており、特定のターゲットに対してだけ反応します。このため、免疫薬は従来の薬剤に比べて、副作用が少なく、狙ったターゲットに対して高い効果を示すことがあります。また、免疫薬は、長期にわたって持続的な効果を持つことが期待されるため、治療後も免疫記憶を形成し、再発を防ぐ可能性があります。 免疫薬の種類には、主に以下のようなものがあります。まず、モノクローナル抗体です。これは、特定の抗原に結合するように設計された抗体であり、がん治療において特に効果を発揮します。例えば、トラスツズマブ（商品名ハーセプチン）は、HER2陽性の乳がんに対して使用されるモノクローナル抗体です。これにより、がん細胞の成長を阻害することができます。 次に、免疫チェックポイント阻害剤があります。これは、免疫系の一部であるT細胞の活動を調整するタンパク質を標的とした薬剤です。がん細胞はしばしば、免疫系から逃れるためのメカニズムを持っていますが、チェックポイント阻害剤はそのメカニズムを阻害し、T細胞ががん細胞をより効果的に攻撃できるようにします。例としては、ペムブロリズマブ（商品名キイトルーダ）があり、悪性黒色腫や非小細胞肺がんなどに用いられています。 さらに、細胞療法も免疫薬の一種に分類されます。特にCAR-T細胞療法は、患者自身のT細胞を遺伝子工学的に修飾してがん細胞を認識させ、攻撃させる方法です。この治療法は、急性リンパ芽球性白血病などに対して高い効果を示しています。 自己免疫疾患の治療においても、免疫薬は使用されています。例えば、インターフェロンや細胞性免疫抑制剤が代表的です。これらは、免疫系の過剰な活動を抑制し、疾患の進行を防ぐことを目的としています。リウマチや多発性硬化症などの治療に広く使用されています。 免疫薬の用途は多岐にわたりますが、特にがん治療においての重要性が増しています。従来の化学療法や放射線療法では効果が薄かったり、副作用が強かったりする場合に、免疫薬は新たな治療の可能性を提供するため、多くの研究が行われています。また、感染症の予防や治療、さらにはワクチンの開発においても免疫薬は重要な役割を果たしています。 関連技術として、バイオテクノロジーや遺伝子工学があります。これらの技術は、新しい免疫薬を開発するための基盤となっており、より効果的で特異的な治療法の実現を可能にしています。また、バイオマーカーの研究は、患者ごとの治療効果の予測や、副作用のリスクを評価するためにも重要です。これにより、個別化医療の進歩が期待されています。 このように、免疫薬は近年の医療の中で非常に重要な位置を占めており、がん治療を始めとするさまざまな疾患の治療において新たなアプローチを提供しています。今後も研究が進むことで、さらなる治療法の確立や、新しい免疫薬の開発が期待されます。また、免疫薬の特性を最大限に活かすためには、医師や研究者、製薬会社の連携が重要であり、臨床試験の実施や効果的な治療法の普及が求められます。免疫薬は、現代医療における革新的な治療手段として、今後ますますその重要性を増していくことでしょう。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer